A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Multiple Dose Study of CK-2127107 in Two Ascending Dose Cohorts of Patients With Spinal Muscular Atrophy (SMA)

Trial Profile

A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Multiple Dose Study of CK-2127107 in Two Ascending Dose Cohorts of Patients With Spinal Muscular Atrophy (SMA)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Aug 2017

At a glance

  • Drugs CK 2127107 (Primary)
  • Indications Spinal muscular atrophy
  • Focus Pharmacodynamics; Therapeutic Use
  • Sponsors Cytokinetics
  • Most Recent Events

    • 17 Aug 2017 Planned End Date changed from 1 Dec 2016 to 1 Feb 2018.
    • 17 Aug 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Feb 2018.
    • 02 Aug 2017 According to a Cytokinetics media release, the company expects data from this study in 1Q of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top